Frovatriptan
Frovatriptan.JPG

Frovatriptan

CLINICAL USE

Acute relief of migraine

DOSE IN NORMAL RENAL FUNCTION

2.5 mg; a second dose can be taken if required after at least 2 hoursMaximum daily dose is 5 mg

PHARMACOKINETICS

  • Molecular weight                           :243.3
  • %Protein binding                           :15
  • %Excreted unchanged in urine     : 10–32
  • Volume of distribution (L/kg)       :3–4.2
  • half-life – normal/ESRD (hrs)      :26/ Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Likely dialysability. Dose as in normal renal function
  • HD                     :Likely dialysability. Dose as in normal renal function
  • HDF/high flux   :Likely dialysability. Dose as in normal renal function
  • CAV/VVHD      :Likely dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Antidepressants: blood levels of frovatriptan increased 27–49% by fluvoxamine – avoid concomitant use; possibly increased serotonergic effects with duloxetine and SSRIs; increased serotonergic effects with St John’s wort – avoid concomitant use
  • Ergot alkaloids: increased risk of vasospasm

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments





    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs